Related Experiment Video

Updated: Nov 14, 2025

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
04:09

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Published on: March 3, 2023

3.4K

Senolytics: Potential for Alleviating Diabetes and Its Complications

Allyson K Palmer1, Tamar Tchkonia1, James L Kirkland1

  • 1Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, Minnesota 55905, USA.

Endocrinology
|March 11, 2021
PubMed

Insights

Senolytic compounds selectively clear aging cells, offering a promising new approach to treat metabolic dysfunction, type 2 diabetes, and related complications. Clinical trials are needed to safely translate these findings into human therapies.

Area of Science:

  • Gerontology
  • Metabolic diseases
  • Cellular biology

Background:

  • Cellular senescence, the accumulation of aging cells, is a key driver of metabolic dysfunction and type 2 diabetes.
  • Senescent cells contribute to the pathogenesis of diabetes and its complications.

Purpose of the Study:

  • To review the role of cellular senescence in type 2 diabetes and its complications.
  • To present evidence for senolytic therapy in preclinical models.
  • To outline senolytic drugs and clinical trial designs for diabetes.

Main Methods:

  • Literature review of cellular senescence in diabetes.
  • Analysis of preclinical data on senolytic interventions.
  • Examination of senolytic drug classes.
  • Discussion of clinical trial design for senolytic therapy in diabetes.

Main Results:

  • Targeting cellular senescence shows promise in preclinical models for improving metabolic function and reducing diabetes complications.
  • Senolytic drugs offer a potential therapeutic strategy for obesity and type 2 diabetes.
  • Intermittent administration of senolytics may improve adherence and reduce side effects.

Conclusions:

  • Cellular senescence is a fundamental aging mechanism implicated in metabolic dysfunction and diabetes.
  • Senolytic therapies represent a novel therapeutic class for treating obesity, diabetes, and their complications.
  • Well-designed clinical trials are essential for translating senolytic discoveries into human treatments.
Keywords:
agingcellular senescencediabetes complicationsdiabetes mellitus

More Related Videos

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

5.0K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

668

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
692
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
430
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
1.5K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.2K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
564
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
504